QIAGEN (QGEN)
(Delayed Data from NYSE)
$42.01 USD
+0.56 (1.35%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $42.02 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum C VGM
Brokerage Reports
QIAGEN N.V. [QGEN]
Reports for Purchase
Showing records 221 - 239 ( 239 total )
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q12 Pre-conference Call Recap - Sales In line - EPS Beats By $0.02 Due to Lower Tax Rate - Acquisitions Perform Fine - BRIC Growth Solid - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q12 Recap - Encouraging Tone Overall - Very Strong Instrument Orders Drive Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q12 First Blush - Sales & EPS Beat Consensus on Strong System Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Expecting In-line 2Q12 - Sequencing Strategy Intriguing
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q12 First Blush - Decent Top line and EPS Beat vs Consensus - GMs and R&D Better, But SG&A Bloated - Broad Geographic Growth - Staying NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q12 Financial Preview - Anticipating Slightly Better Results Driven by Personalized Medicine - Still Skeptical on Full Year - Reaffirming NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Ok 4Q11 Results Cap Off a Rebuilding Year - Guidance on the Soft Side
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q11 First Blush - Consumables Strength Drives Solid Top Line Beat - EPS Beat Less Impressive - 2012 Guidance a Little Light
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q11 Financial Preview - Expecting Slightly Lower Results - Cautious on HPV Despite North American 4Q11 Tender - No Compelling Reason To Own Here
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q11 First Blush - Lackluster Results - Topline Just Shy on HPV Order Distortion in North America -System Sales Solid - Other Income Drives EPS Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q11 Preview - Expecting Results to Edge Past Consensus - Trimming Estimates and PT on More Challenging Macro & GPRO HPV Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q11 Report Ok; More Positives Than Negatives; 2011 Tailwinds Intact; Back Half Acceleration
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G